Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...
You will be redirected to our submission process. Particle therapy is revolutionizing radiation oncology by enabling highly precise, individualized cancer treatments. As technology evolves, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results